During the past decade, Szpital Kliniczny Przemienienia Pańskiego conducted 49 clinical trials. In the 10-year time frame, 49 clinical trials started and 25 clinical trials were completed, i.e. on average, 51% percent of trials that started reached the finish line to date. In the past 5 years, 14 clinical trials started and 20 clinical trials were completed. i.e. 142.9% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Szpital Kliniczny Przemienienia Pańskiego" #1 sponsor was "Hoffmann-La Roche" with 6 trials, followed by "Bayer" with 5 trials sponsored, "Merck Sharp & Dohme LLC" with 3 trials sponsored, "Amgen" with 2 trials sponsored and "BackBeat Medical Inc" with 2 trials sponsored. Other sponsors include 41 different institutions and companies that sponsored additional 47 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Szpital Kliniczny Przemienienia Pańskiego" #1 collaborator was "Massachusetts General Hospital" with 2 trials as a collaborator, "Albany Stratton VA Medical Center" with 1 trials as a collaborator, "Bard Ltd" with 1 trials as a collaborator, "CTI Clinical Trial and Consulting Services" with 1 trials as a collaborator and "California Institute for Regenerative Medicine (CIRM)" with 1 trials as a collaborator. Other collaborators include 30 different institutions and companies that were collaborators in the rest 40 trials.

According to Clinical.Site data, the most researched conditions in "Szpital Kliniczny Przemienienia Pańskiego" are "Coronary Artery Disease" (5 trials), "Ovarian Cancer" (4 trials), "Heart Failure" (3 trials), "Fallopian Tube Cancer" (2 trials) and "Leukemia, Myeloid, Acute" (2 trials). Many other conditions were trialed in "Szpital Kliniczny Przemienienia Pańskiego" in a lesser frequency.

Most popular intervention types in "Szpital Kliniczny Przemienienia Pańskiego" are "Drug" (43 trials), "Device" (16 trials), "Other" (9 trials), "Biological" (8 trials) and "Procedure" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (14 trials), "Carboplatin" (4 trials), "Docetaxel" (4 trials), "Atezolizumab" (3 trials) and "Pembrolizumab" (3 trials). Other intervention names were less common.

The vast majority of trials in "Szpital Kliniczny Przemienienia Pańskiego" are 58 trials for "All" genders, 5 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Szpital Kliniczny Przemienienia Pańskiego". undefined are not yet recruiting, 8 are recruiting, 18 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 30 completed trials in Szpital Kliniczny Przemienienia Pańskiego, undefined suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in Szpital Kliniczny Przemienienia Pańskiego, 7 "Phase 1" clinical trials were conducted, 17 "Phase 2" clinical trials and 32 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 10 trials that are defined as “Not Applicable".

Szpital Kliniczny Przemienienia Pańskiego has several departments that took part in Clinical trials: "Szpital Kliniczny im. Heliodora Święcickiego; Oddzial Hematologii i Transplantacji Szpiku" - 6 trials, "Szpital Kliniczny Przemienienia Panskiego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu, Oddzial Kardiologii - F, ul. Dluga 1/2" - 2 trials, "Szpital Kliniczny im. Heliodora Święcickiego Uniwersytetu Me-Oddzial Ginekologii Onkologicznej ( Sit" - 2 trials